NCT06173375

Brief Summary

The objective of this pilot study is to compare the effectiveness of mailed outreach of two stool based tests, Cologuard and the fecal immunochemical test (FIT) in screening eligible adults ages 45-49 receiving care at the University of California San Diego Health system.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P25-P50 for not_applicable colorectal-cancer

Timeline
Completed

Started May 2024

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 7, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 15, 2023

Completed
5 months until next milestone

Study Start

First participant enrolled

May 15, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

November 4, 2025

Status Verified

October 1, 2025

Enrollment Period

8 months

First QC Date

December 7, 2023

Last Update Submit

October 31, 2025

Conditions

Keywords

screeningearly detectionstool blood test

Outcome Measures

Primary Outcomes (3)

  • Proportion of Colorectal cancer screening completion

    The proportion of individuals who complete any colorectal cancer screening test recommended by US Preventive Services Task Force (colonoscopy, FIT, Cologuard, Sigmoidoscopy or CT Colonography)

    Within 3 months of randomization

  • Proportion of Abnormal stool blood test results

    Among those completing designed interventions (Cologuard or FIT), the proportion of test results yielding an abnormal result.

    Within 3 months of randomization

  • Proportion of Follow-up colonoscopy after abnormal stool blood test result

    Among those with positive stool blood test results, the proportion who complete diagnostic follow-up colonoscopy

    Within 6 months after stool blood test completion

Secondary Outcomes (5)

  • Number of participants opting out of the pilot

    Within 3 months of randomization

  • Number of participants with undeliverable FIT or Cologuard tests (mail fail rate)

    Within 3 months of randomization

  • Number of Adenomas detected

    Within 6 months after screening test completion

  • Number of sessile serrated lesions detected

    Within 6 months after screening test completion

  • Number of colorectal cancer cases detected

    Within 6 months after screening test completion

Study Arms (2)

Mailed Cologuard Outreach

EXPERIMENTAL

Receipt of mailed Cologuard test for colorectal cancer screening to be completed and returned by participant. If test is negative, participant will be advised to undergo another test in 3 years. If test is positive, participant will be advised to schedule colonoscopy for further testing.

Diagnostic Test: Cologuard

Mailed Fecal immunochemical test Outreach

ACTIVE COMPARATOR

Receipt of mailed FIT for colorectal cancer screening to be completed and returned by participant. If test is negative, participant will be advised to undergo another test in 1 year. If test is positive, participant will be advised to schedule colonoscopy for further testing.

Diagnostic Test: Fecal Immunochemical Test

Interventions

CologuardDIAGNOSTIC_TEST

Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.

Mailed Cologuard Outreach

Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.

Also known as: OC-Sensor Test
Mailed Fecal immunochemical test Outreach

Eligibility Criteria

Age45 Years - 49 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Adults ages 45-49 with EHR documentation indicating that the patient has an assigned primary care provider at UCSD Health
  • ≥1 UCSD Health System health visit within the last year
  • Resides in San Diego or Imperial County
  • Currently not up to date with CRC screening
  • Insured by private, public or other health insurance.

You may not qualify if:

  • Up-to-date with screening
  • Prior history of colonic disease, including inflammatory bowel disease, one or more colorectal neoplastic polyps (i.e., adenomas) or colorectal cancer.
  • Prior history of colectomy
  • Lack of health insurance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California San Diego

La Jolla, California, 92126, United States

Location

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Joshua Demb, PhD

    Postdoctoral Researcher

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
PARALLEL
Model Details: Two-arm intervention trial comparing mailed Cologuard outreach (intervention) to mailed FIT outreach (control)
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Postdoctoral Scholar

Study Record Dates

First Submitted

December 7, 2023

First Posted

December 15, 2023

Study Start

May 15, 2024

Primary Completion

December 31, 2024

Study Completion

December 1, 2025

Last Updated

November 4, 2025

Record last verified: 2025-10

Locations